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Cell culture-produced hepatitis C virus (HCV) has been subjected to up to 100 serial passages in human hepatoma cells in the
absence or presence of different doses of alpha interferon (IFN-). Virus survival, genetic changes, fitness levels, and phenotypic
traits have been examined.While high initial IFN- doses (increasing from 1 to 4 IU/ml) did not allow HCV survival beyond
passage 40, a gradual exposure (from 0.25 to 10 IU/ml) allowed the virus to survive for at least 100 passages. The virus passaged
in the presence of IFN- acquired IFN- resistance as evidenced by enhanced progeny production and viral protein expression
in an IFN- environment. A partial IFN- resistance was also noted in populations passaged in the absence of IFN-. All lin-
eages acquired adaptative mutations, andmultiple, nonsynonymous mutations scattered throughout the genome were present
in IFN--selected populations. Comparison of consensus sequences indicates a dominance of synonymous versus nonsynony-
mous substitutions. IFN--resistant populations displayed decreased sensitivity to a combination of IFN- and ribavirin. A phe-
notypic trait common to all assayed viral populations is the ability to increase shutoff host cell protein synthesis, accentuated in
infections with IFN--selected populations carried out in the presence of IFN-. The trait was associated with enhanced phos-
phorylation of protein kinase R (PKR) and eIF2, although other contributing factors are likely. The results suggest that multi-
ple, independent mutational pathways can confer IFN- resistance to HCV andmight explain why no unified picture has been
obtained regarding IFN- resistance in vivo.
Hepatitis C virus (HCV) infects an estimated 180 million peo-ple worldwide, and about 75% of newly infected patients
progress toward a chronic infection, which constitutes a risk for
severe liver diseases such as cirrhosis and hepatocarcinoma (1–4).
HCV is a hepacivirus in the Flaviviridae family characterized by
the error-prone replication and quasispecies dynamics typical of
RNA viruses (2, 5–7). No vaccine is available to prevent HCV
infections or disease, and the current standard of care treatment
consists of the combination of pegylated alpha interferon (IFN-)
and the purine nucleoside analogue ribavirin (1--D-ribofurano-
syl-1-H-1,2,4-triazole-3-carboxamide) (8–10). Type I interferons
(IFNs) such as IFN- are members of a family of cytokines that
constitute key components of the innate immune response to vi-
ruses, and their induction results in an antiviral state of the cell
and suppression of viral replication (11–14). Ribavirin is currently
used to treat a number of human viral infections, and it can dis-
play multiple mechanisms of action, including enhancement of
Th1 antiviral immune responses, upregulation of IFN-stimulated
genes (ISGs), depletion of GTP pools, or viral RNA mutagenesis
(see reviews in references 15, 16 and 17). However, on average
only about 60% of the chronically infected patients show a sus-
tained virological response to treatment with IFN- plus ribavirin
that results in virus clearance (18–21). The molecular and physi-
ological bases of the therapeutic activity of the current combina-
tion treatment with IFN- plus ribavirin are poorly understood. It
might be possible to establish new treatment protocols based on
recently developed directly acting antiviral agents (DAAs), with or
without IFN- and ribavirin (22–27).
Highly variable viruses exploit a number of strategies to coun-
teract selective constraints intended to prevent their replication
(reviewed in reference 7). Mutations that confer resistance to
DAAs generally map in the target protein or in a protein that
interacts with the target (28–30). However, the complexity of the
cellular IFN response pathway is expected to require greater diver-
sity of viral resistance mutations. Current evidence suggests that
the response of HCV to IFN--based therapy is influenced by
several host (i.e., interleukin-28B [IL-28B] gene polymorphisms)
and viral genetic (i.e., viral genotype and population complexity)
factors (31–37).
The advent of cell culture systems for sustained replication of
HCV offers new prospects to approach the evolutionary dynamics
of HCV and the host cell-virus relationship, including the anti-
HCV activity of IFN-. Using these systems, Garaigorta and
Chisari documented that HCV-induced protein kinase R (PKR)
phosphorylation inhibited translation of IFN-stimulated genes
(ISGs) in infected hepatocytes (38). Here we describe the adapta-
tion of the HCV replication system of genotype 2a (39–41) to
perform serial passages of HCV in the Huh-7.5 hepatocyte cell line
with sustained, efficient viral replication for at least 100 serial pas-
sages. This cell culture system allows for investigations on popu-
lation dynamics similar to those carried out with different RNA
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viruses (7). We have subjected HCV to 100 serial passages in the
absence or presence of increasing doses of IFN-. The IFN--
selected populations displayed increased fitness in the presence of
IFN-. Consensus genomic nucleotide sequences of the viral pop-
ulations after 30, 45, and 100 passages revealed multiple mutations
throughout the HCV genome associated with IFN- resistance in
addition to several cell-culture adaptive mutations. Virus pas-
saged in the absence or presence of IFN- displayed partial resis-
tance to IFN- plus ribavirin and a gradual increase in shutoff
host cell protein synthesis. This trait was accentuated in the IFN-
-resistant populations replicating in the presence of IFN-.
MATERIALS AND METHODS
Cells, viruses, and drugs.The origin of Huh-7.5, Huh-7 Lunet, and Huh-
7.5 reporter cell lines and procedures for cell growth in Dulbecco’s mod-
ification of Eagle’s medium (DMEM) have been previously described
(42–45). Infected and uninfected cells were cultured at 37°C and 5% CO2.
The HCV cell culture (HCVcc) derivatives used in the experiments,
Jc1FLAG2(p7-nsGluc2A) and its polymerase-defective negative control
(GNN), have been previously described (46). To control for the absence of
contamination, the supernatants of mock-infected cells maintained in
parallel with the infected cultures were titrated; no infectivity in the mock-
infected cultures was detected in any of the experiments.
A stock solution of alpha interferon 2b (IFN-) (GenScript) was pre-
pared in DMEM at a concentration of 108 IU/ml and stored at 70°C.
Prior to use, the IFN- was analyzed electrophoretically and tested in a
vesicular stomatitis virus infectivity reduction assay. Stock solutions of 0.1
M ribavirin (Sigma) and 10 mM telaprevir (TPV) (Selleck Chemicals)
were prepared in phosphate-buffered saline (PBS) and H2O, respectively,
and stored at 70°C. Prior to use, the stock solutions were diluted in
DMEM to reach the desired concentration.
Production of master infectious virus stock HCV p0 and specific
mutants. Huh-7 Lunet cells were electroporated with 10 g of parental
HCVcc or polymerase-defective negative-control (GNN) RNA tran-
scripts (Gene Pulser Xcell electroporation system; Bio-Rad) (260 V, 950
F) and then subcultured every 3 to 4 days before cells reached confluence
for up to 30 days postelectroporation (47). A viral stock was prepared by
pooling cell culture supernatants from day 17 to day 24 postelectropora-
tion. The viral stock was then concentrated 20-fold using 10,000 molecu-
lar weight cutoff (MWCO) spin columns (Millipore) as indicated by the
manufacturer and stored in aliquots at70°C. To increase virus infectiv-
ity, Huh-7.5 reporter cells were infected with concentrated virus stocks
(multiplicity of infection [MOI] of approximately 0.5 tissue culture infec-
tious doses [TCID50]/cell), and 3 days later the cells were subcultured and
maintained a further 3 days. After a second infection and two subsequent
cell passages, aliquots of the cell culture supernatants were stored and used
in all future experiments as the master HCV viral stock, HCV p0.
The cDNA that expressed HCV p0 was also used as the genomic back-
bone for the construction of three mutant infectious clones, T17A (in E1),
S18G (in E2), and T28P (in NS2), by overlap extension PCR. Two over-
lapping PCR fragments were assembled each for E1-T17A (primers
EcoRI-F plus BCH-O-7 and primers Jc1-E1-R1 plus BCH-O-8), for E2-
S18G (primers Jc1-E1-F1 plus BCH-O-9 and primers NotI-R plus BCH-
O-10), and for NS2-T26P (primers Jc1-LUC-F1 plus BCH-O-13 and
primers Jc1-NS3-R2 plus BCH-O-14) (see Table S1 at http://www.cbm
.uam.es:8080/cv-303/SupplMatPerales.pdf). The fusion PCR products
were then TA cloned into pTZ57R/T vector (Fermentas) and completely
sequenced to confirm that no unwanted mutations had been introduced.
Correct TA clones for the three mutants were digested using EcoRI and
BsiWI, BsiWI and BglII, and BglII and SpeI, respectively, and mutant
genome fragments were subsequently ligated with the similarly digested
parental HCV cDNA clone to construct a full-length infectious HCV
cDNA clone of each mutant. Infectious RNA transcripts were produced
and used to electroporate Huh-7 Lunet cells as described for production
of HCV p0.
Virus titration. Virus titers were determined by calculating the
TCID50/ml (48). Briefly, cell culture supernatants were serially diluted
and used to infect Huh-7.5 cells that had been seeded in 96-well plates at
6,400 cells/well 16 h earlier. Three days postinfection, cells were washed
with PBS, fixed with ice-cold methanol, and stained for the presence of
NS5A using an anti-NS5A monoclonal antibody, 9E10, as described pre-
viously (39).
IFN- toxicity and inhibitory activity. The toxicity of IFN- was
measured in Huh-7.5 reporter cells by seeding 96-well plates at 70% con-
fluence and exposing the cells to up to 108 IU/ml IFN- for 72 h. MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was
added to each well at a final concentration of 500 g/ml; the cells were
incubated 4 h, 100 l of dimethyl sulfoxide (DMSO) was added, and the
optical density was measured at a wavelength of 550 nm. The CC50 (the
concentration of IFN- that results in cytotoxicity for 50% of the cells)
was calculated from four different determinations as described previously
(49), and it was higher than 108 IU/ml for Huh-7.5 reporter cells.
The 50% inhibitory concentration (IC50) of IFN- with respect to
HCV infectivity was determined by seeding Huh-7.5 reporter cells in 24-
well plates at 70% confluence and exposing the cells to serial dilutions of
IFN- (0.1 to 100 IU/ml) for 72 h. IC50s were measured using the virus
titration as described above and calculated relative to the untreated con-
trol levels (defined as 100%).
Cell culture system for long-term serial passage of HCV in the ab-
sence or presence of IFN-. To initiate serial passages of HCV, 4  105
Huh-7.5 reporter cells per well of a 6-well tissue culture plate were infected
with HCV p0 (MOI  0.5 TCID50/cell) for 5 h at 37°C followed by
removal of inoculum and addition of 2 ml of culture medium. Appropri-
ate quantities of IFN- were added to the infected cells that were further
incubated at 37°C for 72 to 96 h. For each subsequent passage, 4  105
Huh-7.5 reporter cells were infected as described above using 0.5 ml of cell
culture supernatant from the previous passage. The MOI for each infec-
tion was calculated from the infectivity values given for each experiment
described in Results, and it ranged between 0.1 and 0.5 TCID50/cell. Pas-
sage number is here abbreviated with p followed by the number (e.g., p10
represents passage 10; viral populations are referred to with a passage
number followed by “IFN” and the number of IU/ml in the cell culture
supernatant in the case of populations passaged in the presence of IFN-).
Mock-infected cells and cells infected with HCV p0 without IFN- treat-
ment were maintained for 100 passages in parallel. No evidence of con-
tamination of mock-infected cells with virus was observed at any time.
Due to increasing cytotoxicity associated with elevated levels of infectious
virus in cultures not treated with IFN-, the infection volume was de-
creased from 500 l to 20 l after passage 59, as indicated in Results.
RNA extraction, cDNA synthesis, PCR amplification, and nucleo-
tide sequencing. Intracellular viral RNA was extracted from infected cells
after each passage using a Qiagen RNeasy kit (Qiagen, Valencia, CA) ac-
cording to the manufacturer’s instructions. Reverse transcription was
performed using AMV reverse transcriptase (Promega), and PCR ampli-
fication of the entire HCV genome was carried out using AccuScript (Agi-
lent Technologies) with specific oligonucleotides (Table S1 [http://www
.cbm.uam.es:8080/cv-303/SupplMatPerales.pdf]). Amplification pro-
ducts were analyzed by agarose gel electrophoresis using the fragments
produced by digestion of -29 DNA with HindIII as molecular mass
standards. Negative controls without template RNA were included in par-
allel to confirm the absence of cross-contamination by template nucleic
acids. Nucleotide sequences of genomic HCV RNA were determined on
the two strands of an amplified cDNA copy as previously described (50).
Numbering of HCV genomic residues is according to JFH-1 accession
number AB047639.
Quantification ofHCVRNAusing qRT-PCR. Quantitative real-time
PCR (qRT-PCR) of HCV RNA was carried out in triplicate using a Light
Cycler RNA Master SYBR green I kit (Roche), as described previously
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(51). The noncoding 5= untranscribed region (5=-UTR) of the HCV ge-
nome was amplified using as primers oligonucleotide HCV-5UTR-F2 (5=-
TGAGGAACTACTGTCTTCACGCAGAAAG [sense orientation]; the 5=
nucleotide corresponds to genomic residue 47) and oligonucleotide
HCV-5UTR-R2 (5=-TGCTCATGGTGCACGGTCTACGAG [antisense
orientation]; the 5= nucleotide corresponds to genomic residue 347).
Quantification was relative to a standard curve obtained with known
amounts of HCV RNA synthesized by in vitro transcription of HCV cDNA
(plasmid GNN). The specificity of the reaction was monitored by deter-
mining the denaturation curve of the amplified DNAs. Negative controls
(without template RNA and RNA from mock-infected cells) were run in
parallel with each amplification reaction to ascertain the absence of con-
tamination with undesired templates.
Relative-fitness assays.Relative fitness was measured by growth com-
petition experiments in the presence or absence of IFN-. Each interferon-
treated HCV population from passages 30, 45, and 100 was mixed at a 1:1
ratio with untreated HCV from passages 30, 45, and 100, respectively.
Growth competition experiments were performed by infecting 4  105
Huh-7.5 cells with each mixture (1.2  104 TCID50 total virus; MOI 
0.03 TCID50/cell) followed by four serial passages in the absence or
presence of IFN- (2 IU/ml for p30 and p45 viral mixtures; 12 IU/ml for
p100 viral mixtures). Genomic regions with nucleotides that differed be-
tween the two competing populations were sequenced to distinguish be-
tween the viruses in the initial mixtures and at each passage (see the data at
http://www.cbm.uam.es:8080/cv-303/SupplMatPerales.pdf). The ratio of
competing viruses at each passage was estimated by measuring the area of
the relevant peaks as described previously (50); discriminatory nucleo-
tides that differ between the two competing viruses were used to deter-
mine the ratio of the two viral populations. The logarithm of this ratio was
plotted against the passage number, and the fitness vector was adjusted to
an exponential equation: y  a  ebx. The antilogarithm of the vector
slope gives the fitness value of the virus tested relative to that of the refer-
ence virus.
Pulse-labeling of infected cells andWesternblot assays.Protein syn-
thesis was analyzed by metabolic labeling of infected cells with [35S]me-
thionine-cysteine ([35S]Met-Cys) followed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) of protein extracts and
fluorography. Proteins were labeled by the addition of 60Ci of [35S]Met-
Cys (Amersham) per ml contained in methionine-free DMEM at 72 h
postinfection. After 1 h of incubation of the cell monolayers with the
radioactive medium, the latter was removed and the cells were harvested
in 0.2 ml of sample buffer (160 mM Tris-HCl [pH 6.8], 2% SDS, 11%
glycerol, 0.1 M dithiothreitol [DTT], 0.033% bromophenol blue). The
samples were boiled for 5 min, and aliquots were analyzed by SDS-PAGE
at 200 V. Fluorography and autoradiography of the gels were done as
described previously (52). The amount of cell extract used for electropho-
retic analysis was normalized to a constant amount of cellular actin, mea-
sured by reactivity with a specific monoclonal antibody (anti--actin
clone AC-15; Sigma).
For Western blot assays, proteins were transferred to a 0.45-m-pore-
size nitrocellulose membrane (Bio-Rad). Blots were developed with the
following antibodies: mouse monoclonal anti-NS5A antibody (9E10
[39]) at a dilution of 1:1,000, mouse monoclonal anti-core (Santa Cruz
Biotechnology) at a dilution of 1:200, mouse monoclonal anti--actin
antibody (clone AC-15; Sigma) at a dilution of 1:1,000, rabbit polyclonal
anti-eIF2 phosphospecific antibody (Invitrogen) at a dilution of 1:300,
rabbit polyclonal antibody anti-eIF2 (Santa Cruz Biotechnology) at a
dilution of 1:200, rabbit monoclonal anti-PKR phosphospecific antibody
(Epitomics) at a dilution of 1:1,000, and rabbit polyclonal anti-PKR anti-
body (Santa Cruz Biotechnology) at a dilution of 1:200. Goat anti-mouse
IgG (Pierce) and donkey anti-rabbit IgG (Amersham) antibodies coupled
to peroxidase were used at a dilution of 1:10,000. The amount of protein
extract used to determine the relative intensities of viral and cellular pro-
teins corresponded to the linear region in the relationship between the
concentration of protein extract and band intensity determined by West-
ern blot analysis.
Nucleotide sequence accession numbers. The genomic nucleotide
sequences for the HCV populations described in the present study have
been deposited in GenBank with accession numbers KC595606 to
KC595624.
RESULTS
Active HCV replication in cell culture and response to IFN-.
Quasispecies dynamics dictates that large population sizes and
active viral replication ensure a dynamic mutant repertoire that
may favor the presence of viral mutants with increased fitness in
the presence of a selective agent (7). To achieve a robust HCV
replication, an initial viral stock (p0) was prepared from the viral
progeny obtained between 17 and 24 days postelectroporation of
Huh-7 Lunet cells with HCVcc RNA; viral production was shown
to steadily increase about 10-fold from day 2 through day 30 post-
electroporation (Fig. S1A [http://www.cbm.uam.es:8080/cv-303
/SupplMatPerales.pdf]). During each passage of the electropo-
rated cells, the supernatant was collected and fresh medium added
to the cell monolayer. Active HCV replication was confirmed by
staining of cells with a NS5A-specific monoclonal antibody (Fig.
S1B [see URL mentioned above]) and by reactivity of core- and
NS5A-specific monoclonal antibodies in Western blot assays us-
ing an extract of infected cells (Fig. S1C [see URL mentioned
above]). Pooled, concentrated cell supernatants yielded viral
preparations p0 and GNN-p0 (negative control). The IC50 of
IFN- under our infection conditions for p0 was 0.43 	 0.33
IU/ml. Its CC50 was
10
8 IU/ml. Thus, the selective (or therapeu-
tic) index (CC50/IC50) was 
2  10
8. To further measure the
sensitivity of p0 to IFN- treatment, the virus was serially pas-
saged in the presence of 1, 2, 5, and 10 IU/ml of IFN- (Fig. S2A
and B [see URL mentioned above]). HCV replication was sus-
tained for at least 10 passages in the absence of IFN-, with a
dose-dependent decrease in the presence of IFN-. Infectivity and
viral RNA progeny production decreased modestly in the pres-
ence of 1 IU/ml of IFN-, while a sharp decrease occurred in the
presence of 2, 5, and 10 IU/ml IFN-, rendering infectivity and
HCV RNA undetectable by passage 4 to 6 (Fig. S2C [see URL
mentioned above]). Thus, the system is adequate to provide a
large viral load to study HCV adaptive mechanisms and the re-
sponse to IFN-.
Selection of IFN--resistant HCV populations during serial
passages in the presence of increasing concentrations of IFN-.
To obtain HCV populations resistant to IFN-, HCV p0 viral
progeny was passaged in either the absence or the presence of
different concentrations of IFN-. Because drug-resistant viral
mutants are often more easily obtained by replicating a virus in the
presence of gradually increasing drug concentrations (53, 54), we
chose to establish three parallel HCV lineages, each involving se-
rial infections under conditions of increasing IFN- concentra-
tions. For simplicity, we distinguish the three lineages with the
terms “low” (initial IFN- concentration of 0.25 IU/ml in the
culture medium), “medium” (initially 0.5 IU/ml), and “high”
(initially 1 IU/ml), with doubling of their corresponding prior
IFN- concentrations at passages 10 and 30 (Fig. 1). The “low”
lineage was further passaged in the presence of IFN-, with the
concentration increased by 1 IU/ml after passages 45, 55, 60, 65,
70, 80, 85, 90, and 95, reaching a final IFN- concentration of 10
IU/ml (Fig. 1A). In addition, two control lineages were estab-
IFN--Resistant HCV Mutants
July 2013 Volume 87 Number 13 jvi.asm.org 7595
lished: HCV p0 passaged in the absence of IFN- and GNN su-
pernatant (replication-defective control) passaged in parallel as a
negative control. Virus infectivity and viral RNA were quantified
for each passage, with striking differences seen between the paral-
lel lineages (Fig. 1B and C). During the first 10 passages, the three
viral lineages behaved similarly and, despite some minor fluctua-
tions in infectious titer, each lineage approached the progeny pro-
duction of HCV p10 (first vertical discontinuous line at p10 in Fig.
1B and C). After the IFN- concentration was doubled at p11, a
decline in progeny production followed in a dose-dependent
manner. Interestingly, the “low” and “medium” lineages that were
increased to 0.5 and 1 IU/ml of IFN-, respectively, at p11 showed
a decrease in viral production that was more accentuated than
when p0 was subjected to those same IFN- concentrations (com-
pare p1 to p10 with p11 to p20 in Fig. 1B and C). Thus, a history of
HCV replication in the presence of IFN- enhanced the sensitivity
of the virus to IFN-.
The “medium” and “high” lineages showed decreased viral
production between p18 and p26, with some values below the
detection limit, prior to a sharp recovery of virus production in
both lineages by p30 (Fig. 1B and C). Thus, a severe population
bottleneck occurred in the “medium” and “high” lineages but not
in the “low” lineage. As a consequence of raising the IFN- con-
centration to 4 IU/ml beginning at p31, the “high” lineage had
infectivity and viral RNA levels below the limit of detection by p40
(Fig. 1B and C). HCV acquired resistance to IFN-, as suggested
by the high level of progeny production attained by the “low”
lineage in the presence of 10 IU/ml of IFN- at p95 to p100. This
progeny level was comparable to that of HCV p100 in the absence
of IFN- (Fig. 1B and C). In contrast, progeny production of the
FIG 1 Long-term serial passage of HCV in the absence or presence of increasing concentrations of IFN-. (A) Huh-7.5 reporter cells were infected with HCV
p0 to initiate four parallel lineages: “No IFN-” (absence of IFN-); “low” IFN- (initially 0.25 IU/ml IFN-); “medium” IFN- (initially 0.5 IU/ml IFN-); and
“high” IFN- (initially 1 IU/ml IFN-). The colored boxes indicate the concentrations of IFN- (in IU/ml) added to the culture medium in the successive
passages. The “medium” and “high” lineages extended only to passage 45. (B) Infectious viral titers of the supernatants as a function of passage number, color
coded as described for panel A. (C) Intracellular viral RNA (quantified by real-time PCR) of the same samples as described for panels A and B. The crosses in the
abscissae of panels B and C indicate measurements upon serial infection with mutant GNN used as a negative control. No infectivity and viral RNA were rescued
upon subjecting p45 of the “high” lineage to 10 serial passages in the absence of IFN-. Conditions for the infections, drug treatments, determination of HCV
infectivity, and quantification of HCV RNA, as well as the positive and negative controls included in the assays, are described in Materials and Methods.
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“high” lineage became undetectable after only a few passages in
the presence of 4 IU/ml of IFN- (Fig. 1B and C). These results
suggest a difference in fitness cost of short-term (few passages)
versus long-term (many passages) adaptation of HCV to IFN-.
IFN- resistance of passaged HCV populations. To obtain
additional evidence that HCV populations passaged in the pres-
ence of IFN- acquired an IFN--resistant phenotype, popula-
tions from p30, p45, and p100 were subjected to 10 further pas-
sages in the absence or presence of IFN- and their behavior was
compared with that of the initial virus p0. The amounts of infec-
tivity and viral RNA indicate higher HCV progeny production in
the presence of IFN- of those populations that had a passage
history in the presence of IFN- compared with the population
with a passage history in the absence of IFN- (Fig. 2A). Differ-
ences in viral protein expression were confirmed by Western blot
analysis of HCV-specific proteins in intracellular extracts from
cells infected with viruses from passages 30, 45, and 100 (Fig. 2B).
Growth competition assays further confirmed IFN- resistance
phenotypes in the HCV passaged in the presence of IFN- relative
to the virus passaged in the absence of IFN- (Fig. 2C and Table S2
[http://www.cbm.uam.es:8080/cv-303/SupplMatPerales.pdf]). A
history of replication in the presence of 2 IU/ml of IFN- did not
confer higher resistance than a history of replication in the pres-
ence of 1 IU/ml (compare the p30 IFN1/p30 and p45 IFN2/p45
panels in Fig. 2C). Also, p30 IFN2 had a lower fitness relative to
p30 in the absence or presence of 2 IU/ml IFN- (Fig. 2C and
Table S2 [see URL mentioned above]). The fitness decrease might
have contributed to loss of infectivity of the “high” lineage before
p45 (compare with Fig. 1B and C). Unexpectedly, HCV p30, p45,
and p100, passaged in the absence of IFN-, displayed a clear
resistance to IFN- compared with p0 (Fig. 2A). Several mecha-
nisms may account for partial IFN- resistance in HCV popula-
tions not exposed previously to exogenous IFN-, and this point is
under investigation (see Discussion). Thus, passage of HCV in
Huh-7.5 cells in the presence of increasing concentrations of
IFN- results in selection of HCV populations that display an
increased capacity to replicate in the presence of IFN-.
Mutations in HCV populations passaged in the absence or
presence of IFN-. To evaluate the genetic diversification of the
different HCV populations passaged in the absence or presence of
IFN- and to detect possible mutations associated with IFN-
resistance, the consensus nucleotide sequence of the entire ge-
nome of HCV populations after 30, 45, and 100 passages in the
absence or presence of IFN- was compared with that of the pa-
rental HCV p0 (Tables S3 to S9 [http://www.cbm.uam.es:8080/cv
-303/SupplMatPerales.pdf]). A total of 115 different mutations
were identified with a dominance of transitions (74%) versus
transversions (26%) (55). The ratio of nonsynonymous to synon-
ymous mutations, corrected per nonsynonymous and synony-
mous sites (dN/dS), gave a range of 0.2187 to 0.4444 (average,
0.3474) for comparisons between populations passaged in the ab-
sence of IFN- and a range of 0.1929 and 1.2500 (average, 0.4489)
for comparisons between populations passaged in the presence of
IFN- (dN/dS ratios for each comparison are given in Table
S7[see URL mentioned above]). The mutation frequencies (cal-
culated relative to the genomic sequence of p0) were very similar
for the populations passaged in the absence of IFN- and for those
passaged in its presence, with average values of 2.6 103 substi-
tutions per nucleotide (s.n1) (range of 4.1 103 to 1.5 103
s.n1) and 2.3  103 s.n1 (range of 4.7  103 to 1.5  103
s.n1), respectively. Thus, the levels of diversification of HCV with
regard to the consensus genomic sequence were comparable in the
presence and absence of IFN-. The HCV genotype 2a chimera
used as the parent in our experiments has a Gaussia luciferase
(Gluc) gene inserted between p7 and NS2 (46). By p30, the first
516 nucleotides (nt) of the 576-bp Gluc gene had been spontane-
ously deleted in all lineages and remained so in all viruses se-
quenced at p45 and p100.
The amino acid replacements found in the different popula-
tions (Fig. 3) could be divided into several classes: (i) replacements
acquired by all populations examined, irrespective of IFN- treat-
ment (i.e., N34D in E2, N17D in p7, and Y618F in NS3); (ii)
replacements that were associated with passage with IFN- treat-
ment and that tended to revert when the selective pressure of
IFN- was removed (i.e., T17A in E1 and S18G in E2 of “low”
lineage p30 and p45 and K122Q in NS3 of “high” lineage p30); (iii)
substitutions found only in populations passaged in the presence
of IFN- that did not revert when the virus was further passaged in
the absence of IFN-; and (iv) replacements that we could not
associate with resistance to IFN-. Each passage condition yielded
a unique set of amino acid substitutions (Fig. 3).
To test whether individual amino acid substitutions could con-
fer IFN- resistance, we prepared HCVcc encoding amino acid
replacements T17A (in E1), S18G (in E2), and T28P (in NS2)
selected under conditions of “low,” “medium” and “medium-
high” IFN- concentrations, respectively (Fig. 1). Because these
amino acid substitutions may impair fitness and T17A (in E1) and
S18G (in E2) reverted upon virus passage in the absence of IFN-,
we prepared minimal virus stocks, ascertained that they included
the mutations, and tested infectious virus progeny production in a
single infection at a low MOI. The results (Fig. 4) indicate that
while HCVcc did not produce detectable infectious progeny in the
presence of IFN-, the three mutants yielded progeny in the pres-
ence of IFN-. Thus, despite lacking fitness-enhancing genomic
mutations, these mutant viruses displayed an IFN- resistance
phenotype.
Response to a high IFN- level and to IFN- plus ribavirin.
To investigate the response of HCV populations passaged 45 times
in the absence or presence of IFN- to higher IFN- concentra-
tions, viral populations p45, p45 IFN1, and p45 IFN2 were sub-
jected to 10 serial passages in the presence of IFN- (12 IU/ml). A
remarkable resistance of populations passaged 45 times in the
presence of IFN- (2 IU/ml) was observed relative to that of the
parental virus p45 (Fig. 5A).
To investigate the response of HCV populations passaged in
the absence or presence of IFN- to a combination of IFN- and
ribavirin, viral populations of passages 45 and 100 were subjected
to 10 serial passages in either the absence or the presence of IFN-
plus ribavirin. The results show a modest increase of resistance to
IFN- plus ribavirin of p45 IFN1 and p45 IFN2 relative to the
parental virus (Fig. 5B) and a remarkable resistance of the popu-
lation passaged 100 times in the presence of elevated IFN- (12
IU/ml) relative to p100 (Fig. 5C). Thus, resistance to IFN- is
reflected in a diminished response to the combination of IFN-
plus ribavirin.
Phenotypic effects of IFN- selection. To investigate whether
IFN- resistance could be associated with some common pheno-
type regarding intracellular protein expression, populations p0,
p45, p45 IFN1, p45 IFN2, p100, and p100 IFN10 were used to
infect Huh-7.5 reporter cells at an MOI of about 0.03 TCID50/cell,
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and 56 h later cells were treated with 2 IU/ml (for p0 and p45
populations) and 12 IU/ml (for p100 populations) of IFN- for 16
h. Under these conditions, at the time of labeling at least 90% of
the cells are infected. (Preliminary experiments showed that under
our experimental conditions, maximal inhibition of host cell pro-
tein synthesis was achieved when IFN- was added at the peak of
the infection). The infected and mock-infected cultures were
pulse-labeled with [35S]Met-Cys, and proteins were extracted and
analyzed electrophoretically and by Western blotting with specific
antibodies (Fig. 6). Populations passaged in the absence of IFN-
produced a shutoff host cell protein synthesis that increased with
the virus passage number. Shutoff was more evident in popula-
tions with a history of passage in the presence of IFN- (Fig. 6A,
rowIFN). Shutoff was further enhanced when the infection was
carried out in the presence of IFN- (Fig. 6A, rowIFN). Infec-
tion in the presence of IFN- increased the level of shutoff, and the
effect was more prominent with IFN--resistant populations at
p45. This enhancement was lost with IFN--resistant populations
at p100, presumably because they had acquired a high shutoff
activity without IFN- (Fig. 6A, row 	IFN). Thus, the IFN--
selected populations accentuated a phenotypic trait that was par-
tially expressed as a result of passage of the virus in Huh-7.5 cells.
Since host cell protein synthesis can be shut off by phosphory-
lation of translation initiation factor eIF2 and a candidate to
exert such a control is PKR, we tested by Western blotting the
phosphorylation state of PKR and its substrate eIF2 under our
infection conditions (Fig. 6B). As expected, infections in the pres-
ence of IFN- resulted in enhanced PKR expression (Fig. 6B). An
increase of the ratio of the phosphorylated to nonphosphorylated
forms of PKR and eIF2 proteins was observed with all viruses in
the presence of IFN- compared with the same infection in the
absence of IFN-. The increase was slightly higher for the p100
virus with a history of passages in the presence of IFN-, but it was
similar for p45 viruses, despite a pronounced decrease in host cell
protein synthesis in the infections with p45 IFN1 and p45 IFN2
viruses (Fig. 6B). Viral protein expression and progeny produc-
tion were not significantly affected, as expected from the fact that
HCV translation is internal ribosome entry site (IRES) dependent
and may be less affected by eIF2 phosphorylation (56, 57) (Fig.
6C). As a control, under the same conditions, telaprevir did not
increase shutoff host cell protein synthesis in any of the viral pop-
ulations (Fig. S4 [http://www.cbm.uam.es:8080/cv-303/Suppl
MatPerales.pdf]), further supporting the idea that the IFN- en-
vironment may be directly involved in the shutoff trait. Under
these treatment conditions (leading to a less than 4-fold decrease
in viral yield), IFN- and telaprevir (an inhibitor of HCV NS3)
did not cause a significant reduction of infectious virus produc-
tion. Passage of the virus in the presence of IFN-may select for
viral populations with mutations at several viral genes that display
an enhanced capacity to suppress host protein synthesis in the
presence of IFN-.
DISCUSSION
Replication of RNA viruses in cell culture has provided an ex-
tremely useful tool to study the response of viruses to selective
constraints and passage regimens under controlled conditions.
No fundamental discrepancies have been observed between the
basic adaptive mechanisms displayed by viruses in cell culture and
in vivo, a fact which has greatly improved the understanding of
viral quasispecies dynamics (reviewed in reference 7). The possi-
bility of completing infectious cycles of HCV in human hepatoma
cells (39–41) renders HCV amenable to studies of virus evolution
and virus-host interactions in cell culture (58). Here we have
adapted the HCVcc–Huh-7.5 virus-cell system to show that a ro-
bust, sustained viral replication can be maintained for at least 100
passages. We have explored the response of HCV to IFN- treat-
ment, which is a major component of the current standard of care
treatment for HCV infections. Previous studies that investigated
whether HCV mutations were associated with unsuccessful IFN-
therapy have not yielded conclusive results (34, 59–65). In con-
trast to what has been generally observed with standard antiviral
agents that target a defined viral function (53, 54), a history of
passage of HCV in the presence of low concentrations of IFN-
did not prepare the virus to overcome higher IFN- doses, at least
not immediately. However, we have observed long-term fitness
gains (measured in an IFN- environment) upon virus replica-
tion in the presence of IFN- (compare Fig. 1 and 2). A difference
between IFN- and DAAs with regard to low drug concentrations
in preparing the virus to attain drug resistance may relate to the
triggering by IFN- of multiple pathways leading to an antiviral
state in the cells. In the case of Huh-7.5 cells, this antiviral state is
likely to involve the JAK/STAT system since Huh-7.5 cells—a
clonal derivative of Huh-7 cells that supported effective HCV rep-
lication (42)—include a substitution in the first CARD domain of
FIG 2 Interferon resistance of HCV p0 passaged in the absence or presence of IFN-, as determined by infectious progeny production in the cell culture
supernatant. (A) The upper box indicates the viral populations subjected to analysis. The blue symbols for p30, p45, and p100 represent the populations that
resulted from passaging HCV p0 30, 45, and 100 times, respectively, in the absence of IFN-. Yellow, red, and green symbols represent populations that resulted
from passaging HCV p0 30, 45, and 100 times in the presence of the indicated IFN- concentrations. The number following IFN corresponds to the IFN-
concentration at the indicated passage. Each of the populations was subjected to 10 passages in the absence (left panels) or presence (concentration given in the
filled inset in each panel) of IFN-. No infectious virus was detected for the “high” lineage after passage 40 (see Fig. 1B); thus, only p30 was tested for this lineage.
The corresponding intracellular RNA levels are given in Fig. S3 (http://www.cbm.uam.es:8080/cv-303/SupplMatPerales.pdf). (B) At 72 h postinfection (h.p.i.)
(one passage), cellular extracts were subjected to SDS-PAGE and analyzed by Western blotting using monoclonal antibodies specific for the NS5A, core, and actin
proteins. Procedures are described in Materials and Methods. (C) Relative fitness values of interferon-resistant HCV mutants, in the absence or presence of
IFN-. The mutant populations from “low,” “medium,” and “high” lineages were mixed with the HCV from p30, p45, and p100 (without IFN-). Growth
competition experiments were performed by infecting Huh-7.5 cells with each mixture (MOI 0.03 TCID50/cell) followed by four serial passages in the absence
or presence of IFN- (2 IU/ml for p30 and p45 viral mixtures; 12 IU/ml for p100 viral mixture). The asterisk indicates that for the competition depicted by the
yellow bar, the relative fitness value was calculated based on changes in population ratios determined during a single passage (at 24, 48, or 72 h.p.i.) rather than
4 passages. Viral RNA present in the initial mixtures and at each passage was sequenced, and the proportion of the two competing populations was estimated by
comparison of the areas of the relevant nucleotide peaks. Mean fitness values of each IFN--resistant population relative to HCV p30, p45, or p100 in the presence
or absence of IFN- are plotted, with error bars indicating the standard deviations. The nucleotide residues that differ between the two competing viruses and
whose peak areas were used to calculate the proportion of the two viral populations and the individual fitness values used to calculate the average and standard
deviations are given in Table S2 (http://www.cbm.uam.es:8080/cv-303/SupplMatPerales.pdf). Relative fitness values of greater than or less than 1 indicate mutant
populations that have increased or decreased fitness, respectively, relative to HCV p30, p45, or p100. Procedures are detailed in Materials and Methods.
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RIG-I that prevents the association of RIG-I with mitochondrial
anti-viral signaling (MAVS), rendering the RIG-I pathway defi-
cient (66, 67). The IFN--mediated antiviral state may provide an
unfavorable environment for the virus that initially cannot find
mutations to maintain or increase its fitness. Overt IFN- resis-
tance was achieved by extensive passage of HCV under conditions
of gradually increasing IFN- concentrations.
Three amino acid substitutions (N34D in E2, N17D in p7, and
B
A
FIG 3 Amino acid substitutions (relative to the initial infectious transcript HCVcc) in the consensus genome sequences of p0 after 30, 45, and 100 passages in
the absence or presence of IFN-. (A) Proteins core, E1, E2, p7, NS2, NS3, NS4A, and NS4B. (B) Proteins NS5A and NS5B. HCV proteins containing
nonsynonymous mutations are indicated on the top row, with the numerical position and single-letter code of the original amino acid listed directly below.
Amino acids are numbered individually for each protein. Colored panels indicate numbers of passages in the absence of IFN- (blue, top) or in the presence of
IFN- in the “low” (yellow), “medium” (pink), or “high” (green) lineages (as described for Fig. 1). Boxes on the left indicate passage history, including passage
number (p) and the IFN- concentration at the time of collection, sometimes followed by a number in brackets indicating a further 10 passages in the absence
([p10 IFN 0]) or presence ([p10 IFN 2] or [p10 IFN 12] of IFN-; the number following IFN indicates the number of IU/ml of IFN- included in the culture
medium). Single-letter amino acid codes are used to indicate substitutions discovered in each sequenced viral population; two letters separated by a slash indicate
a mixture of the indicated amino acids in the population. An asterisk means that the mutant amino acid is present at a proportion of 25% or lower. No infectious
virus was recovered from the “high” lineage after p40 (see Fig. 1B); thus, only p30 IFN 2 and p30 IFN 2 [p10-IFN 0] were included in the analysis. Sequences
correspond to the populations described for Fig. 1. To facilitate comparisons, the amino acid substitutions using the nomenclature of HCV strain H77 (129) are
given in Table S10 (http://www.cbm.uam.es:8080/cv-303/SupplMatPerales.pdf). Procedures for RT-PCR amplification of the entire genome and nucleotide
sequencing are described in Materials and Methods and in the data at http://www.cbm.uam.es:8080/cv-303/SupplMatPerales.pdf.
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Y618F in NS3) were detected in all passaged HCV populations in
both the absence and the presence of IFN- (Fig. 3). Previous
studies have described adaptive mutations throughout the ge-
nome when passaging JFH-1-derived viruses (68–79). Specifically,
N34D in E2 results in the loss of a well-characterized N-glycosy-
lation site (E2N1) that has been linked to modulation of entry
functions of HCV envelope proteins without interfering with viral
morphogenesis (78). Another report investigating N34S described
enhanced entry, leading to a rapid amplification via efficient
spreading (70). Amino acid 17 in p7 is an essential structural de-
terminant for the p7 ion channel and may play a role as a pH
sensor. Replacement of N17 by D may favor a more optimal func-
tion of the p7 (79) and could also increase viral production due to
enhancement of assembly/morphogenesis steps (76). Y618F is lo-
calized in the helicase domain of NS3, though its significance with
respect to HCV adaptation to Huh-7.5 cells is unknown. In most
lineages, amino acid C298 was exchanged for an arginine in the
absence of IFN- or a tyrosine in the presence of IFN-. C298R
has been also described as increasing infectious virus production
and may play a role in regulating the release of infectious particles
into the cell culture (68). The presence of these amino acid sub-
stitutions across HCV lineages suggests that they might contribute
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FIG 4 Characterization of mutant HCV viruses with amino acid changes
T17A in E1, S18G in E2, and T28P in NS2. (A) Huh-7 Lunet cells (3  106)
were electroporated with 10 g of each RNA, as previously described (47).
Electroporated cells were passaged every 3 to 4 days before cells became con-
fluent for a total of 3 passages (11 days postelectroporation). Cell culture su-
pernatants from each passage were pooled and concentrated 20-fold using spin
columns. Each infectious virus stock was used to infect Huh-7.5 reporter cells
for five serial passages. (B) Supernatants from passage 3 were sequenced in
order to confirm the presence of mutations. (C) Infectivity in the absence and
presence of IFN- was determined for each mutant virus using supernatants
from passage 3 and compared with infectivity of wild-type HCVcc. The dis-
continuous line indicates the limit of detection. Infectious clone construction
and procedures are described in Materials and Methods.
FIG 5 Response of HCV populations to high IFN- concentrations and to the
combination of IFN- and ribavirin (IFN-R). The upper box indicates the
viral populations subjected to analysis. Blue symbols corresponding to p0, p45,
and p100 represent the populations that resulted from passaging HCV 0, 45,
and 100 times, respectively, in the absence of IFN-. Yellow and red symbols
indicate populations that resulted from passaging HCV 0, 45, and 100 times in
the presence of IFN-, with the IFN- concentration given for each lineage.
The number following “IFN” corresponds to the IFN- concentration at the
indicated passage. (A) p45 viruses passaged in the presence of a high IFN-
concentration. Each of the populations was subjected to 10 passages in the
presence of 12 IU/ml IFN-, and infectious progeny production in the cell
culture supernatant (left panel) and intracellular progeny RNA levels (right
panel) were determined. (B) p45 viruses passaged in the presence of IFN-R.
Each of the populations was subjected to 10 passages in the presence of 2 IU/ml
IFN-R (50 M), and infectious progeny production in the cell culture
supernatant (left panel) and intracellular progeny RNA levels (right panel)
were determined. (C) p100 viruses passaged in the presence of IFN- using the
combination treatment IFN-R. Each of the populations was subjected to 10
passages in the presence of 2 IU/ml plus ribavirin (50 M), and infectious
progeny production in the cell culture supernatant (left panel) and intracellu-
lar progeny RNA levels (right panel) were determined. Procedures are de-
scribed in Materials and Methods.
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FIG 6 The effect of infection by passaged HCV populations on host cell protein synthesis in the absence and presence of IFN-. (A) Huh-7.5 cells were either
mock infected or infected with the indicated HCV populations for 56 h. Subsequently, cells were treated with IFN- (IU/ml indicated at the top) for 16 h before
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a significant general fitness advantage, allowing for increased viral
production in the absence or presence of IFN-.
This study has identified amino acid substitutions in every
HCV protein except NS4A (Fig. 3 and Tables S3 to S9 [http://www
.cbm.uam.es:8080/cv-303/SupplMatPerales.pdf]) that became
dominant (composed the majority of genomes in the mutant
spectra) in the populations passaged in the presence of IFN-. The
comparisons suggest that different substitutions at structural (not
expressed in replicon systems) and nonstructural proteins can
play a role in IFN- resistance, though we have not distinguished
substitutions that provide bona fide IFN- resistance from sub-
stitutions that confer a fitness gain once key IFN- resistance mu-
tations have occurred. Also, we cannot exclude the possibility that
some synonymous mutations may affect viral fitness (80). Several
HCV proteins are known to abrogate or decrease the effects of
IFN-. The core protein can counteract IFN-stimulated gene
(ISG) expression by interfering with JAK/STAT signaling (81–83),
and substitutions at positions 70 and 91 resulted in a significantly
decreased cellular response to IFN- treatment in vitro (84); sub-
stitution G90A—present in the “low” lineage as a mixture at p45
and dominant at p100 (Fig. 3)— by virtue of being the neighbor to
position 91 might confer a similar phenotype. E2 targets the IFN-
-induced PKR, and it has been suggested that this interaction
may prevent the antiviral effects of IFN- (85). E2 substitution
S18G (present in the “low” lineage by p30), located within hyper-
variable region 1 (HVR1) of E2, has been previously linked to IFN
resistance in human patients (65). Substitution E2 L283Q (pres-
ent in the “low” lineage by p100) is within the region of sequence
identity shared among the phosphorylation sites of PKR, eIF2,
and HCV E2 (85). The protease NS3-4A can cleave TRIF and
IPS-1/Visa/MAVS/CARDIF, which are essential for IFN- and -
induction (86–88).
The possible contribution of NS5A to IFN- resistance has
been the focus of many studies (89–100). Amino acid substitu-
tions within a 40-amino-acid stretch in NS5A of HCV of genotype
1b correlated with a complete response to IFN- therapy (89,
101); the corresponding region was termed the IFN sensitivity-
determining region (ISDR). This correlation was confirmed by
other groups (102–106) but was not supported for HCV from
other cohorts infected with genotype 1b or with other genotypes
(107–113). The ISDR is part of a domain of NS5A that interacts
with PKR; the ensuing decrease of PKR activity may permit HCV
to avoid the antiviral effects of IFN- (91, 92, 114, 115). In our
study, substitutions N248H and E269K found in the “medium”
lineage at p45 and S272P in the “low” lineage (mixed at p45 and
dominant by p100) are located within the ISDR. Studies on the
mechanisms by which NS5A counteracts IFN- activity have not
given conclusive results (91, 93–95, 112).
There are several possibilities to explain the disparity of results
reported for HCV IFN- resistance: several HCV genes may be
involved, multiple IFN- resistance pathways may be available to
HCV, the selected pathway may depend on key population pa-
rameters (viral load, replicative capacity, quasispecies diversity,
occurrence of genetic bottlenecks [7, 35]), and accompanying
mutations may obscure the role of key mutations in IFN- resis-
tance, among other possibilities. In cell-HCV replicon systems
that require passage of the cells, the mutations observed in HCV
may be conditioned by mutations in the cells that coevolve with
the HCV replicon (75, 96, 116, 117). Furthermore, selection of a
cellular IFN- resistance determinant may render unnecessary the
selection of viral modifications to achieve an equivalent pheno-
type.
The HCVcc populations that were passaged 45 and 100 times
in the absence of IFN- acquired not only partial resistance to
IFN- (despite not having been exposed to IFN- [Fig. 2 and 3])
but also the ability to suppress host cell protein synthesis (Fig. 6).
It is unlikely that endogenous IFN produced by Huh-7.5 cells
could provide a sufficiently selective constraint for the observed
resistance, because Huh-7.5 cells have been reported not to ex-
press detectable IFN levels (66, 67). A possible alternative expla-
nation is that in the exploration of sequence space inherent to
unrestricted (large population) passages of HCV, subpopulations
able to cope with the host cell response— generally manifested in
the form of protein expression— gradually replace their ancestors.
Such replacement is expected to be accelerated by the presence of
IFN-. An alternative possibility is that as the quasispecies ex-
pands, it becomes enriched in IFN- resistance mutations. This
would represent an extension of previous evidence of the presence
of drug-resistant mutants never exposed to the corresponding
drug (118–123; other examples are reviewed in reference 7). Evo-
lution of HCV toward IFN- resistance in the absence of IFN-
could be due to the chance occurrence of adaptive mutations that
might also confer IFN- resistance or a general fitness gain (due to
repeated passages) that renders the virus more resistant to IFN-
(for example, C298R, C298Y in NS5A, N34D in E2, or N17D in p7;
see Fig. 3). This point is under investigation. The fact that multi-
ple, different mutations in the HCVcc lineages can lead to de-
creased IFN- sensitivity may explain why no unified picture on
the molecular basis of HCV IFN- resistance has been obtained in
vivo, where additional environmental variables operate. Further-
more, different HCV isolates may not respond in similar manners
to the selective pressure of IFN-. In particular, the rescued
HCVcc is rather unique in displaying high infectivity for Huh-7.5
cells, and it is not clear whether it shows a behavior representative
of other HCV isolates (46, 58, 124).
A phenotypic trait associated with IFN- resistance identified
in the present study is an enhanced capacity of the virus to evoke a
shutoff host cell protein synthesis in the presence of IFN-. This
proteins were labeled with [35S]Met-Cys for 1 h (top box and headings; “No virus” means mock-infected cells). Cell extracts were subjected to SDS-PAGE and
visualized by autoradiography as described in Materials and Methods. The numbers indicate the percentages of actin protein determined by densitometric
scanning of the corresponding protein band and normalized to the value obtained in the absence of infection and IFN- treatment (IFN row) or to the value
obtained in the absence of infection but presence of IFN- treatment (IFN row) or to the value obtained in the absence of IFN- treatment for each virus (	IFN
row). (B) Cellular extracts were subjected to SDS-PAGE and analyzed by Western blotting using antibodies specific for the phosphorylated and nonphospho-
rylated forms of PKR and eIF2. The amount of cellular proteins was monitored by the amount of actin and visualized by Western blotting (actin panels). The
bottom panels indicate the ratio of phosphorylated to nonphosphorylated forms of PKR and eIF2 calculated from the densitometry of the relevant bands. (C)
Virus-specific proteins were analyzed by reactivity with specific monoclonal antibodies (NS5A and core) in Western blot assays. Determinations of virus titers in
the supernatants of the infected cells at 72 h.p.i. in the absence and presence of IFN-were carried out in triplicate using the titration assay described in Materials
and Methods. The individual titer values are given in Table S11 (http://www.cbm.uam.es:8080/cv-303/SupplMatPerales.pdf).
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result is in agreement with the observation that HCV triggers the
phosphorylation of PKR and eIF2 as a means to attenuate pro-
tein expression, including that by ISGs (38, 125, 126). However,
the difference in shutoff among viral populations was not consis-
tently reflected in the ratio of phosphorylated to nonphosphory-
lated forms of PKR and eIF2 (Fig. 6A and B). Thus, other host
factors related to translation regulation and viral proteins are
likely involved. The IFN--resistant populations obtained in the
present study display partial resistance to IFN- plus ribavirin,
and they will allow probing the effects of viral fitness and the
IFN- resistance phenotype on the response to the new-genera-
tion DAAs. Thus, IFN--resistant HCV populations may provide
a useful tool to penetrate some aspects of HCV biology that were
previously beyond the reach of replicon-based systems. The use of
IFN--resistant HCV populations and large HCV populations
that may mimic a persistent chronic infection would also be a
valuable tool in the design of new antivirals or the testing of new
antiviral regimens based on lethal mutagenesis (127, 128).
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